Semaglutide vs Tirzepatide: How the Two Mechanisms Compare

Reviewed by Thomas Okafor, PhD · Last reviewed October 22, 2026

Semaglutide activates one gut-hormone receptor, the GLP-1 receptor. Tirzepatide activates two, GIP and GLP-1. That single structural difference drives most of what separates them in the research literature. Both are FDA-approved prescription medicines with large human trial programs, and both are peptides, which is why they come up so often in peptide science. Key takeaways:

• 🧪 Mechanism: semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist that, in pharmacology studies, engages the GIP receptor more strongly.
• 👤 Human trials: both have multiple phase 3 randomized trial programs.
• 👤 Head to head: two open-label randomized trials compared them directly, one in type 2 diabetes and one in obesity without diabetes.
• 👤 Side effects: gastrointestinal events were the most common in both drugs’ trials.

KlowStack covers the science behind these molecules and doesn’t give medical advice. Anyone weighing these medicines should talk with a clinician. Research-grade peptides sold online aren’t the approved drugs, as our Medical Disclaimer explains.

Quick Comparison Table

The bottom rows look identical because the two drugs share a class warning. The top rows hold the real difference: one receptor versus two.

What GLP-1 and GIP Do in the Body

GLP-1 and GIP are incretins, hormones released from the gut after eating that boost insulin release when blood sugar is high. GLP-1 also lowers glucagon, slows stomach emptying and signals fullness to the brain. GIP’s role in body weight has been debated, because both activating and blocking its receptor have been studied. The incretin effect describes something researchers noticed decades ago: glucose taken by mouth triggers more insulin than the same glucose given by vein. Gut hormones explain the difference.

• GLP-1 comes from L-cells in the lower gut. 👤 and 🐭 In human physiology and animal studies, it raises insulin in a glucose-dependent way, lowers glucagon, slows gastric emptying and acts on appetite centers in the brain.
• GIP comes from K-cells in the upper gut. It also raises insulin when glucose is high, and it acts on fat tissue and, likely, the brain.

GIP is the puzzle. For years, some researchers argued that blocking the GIP receptor should help with weight, and others argued that activating it should. A 2026 review in the Annual Review of Nutrition calls it “the paradox” of GLP-1/GIP combination therapies, and a 2025 review in Diabetes lays out the case for GIP receptor antagonists. Tirzepatide took the activation route, while GIP-receptor blockers remain under study.

How Semaglutide Works

Semaglutide is a modified version of human GLP-1 with two amino acid changes and a fatty acid side chain. The changes protect it from rapid breakdown, and the side chain lets it ride on albumin in the blood, which is how it lasts long enough for once-weekly use. 🧪 Novo Nordisk scientists described its design in a 2015 Journal of Medicinal Chemistry paper. Semaglutide “has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34))” and carries a fatty acid attached at lysine 26. Natural GLP-1 lasts only minutes in the blood. Swapping in Aib at position 8 shields it from DPP-4, the enzyme that normally chops it up, and the fatty acid boosts albumin binding. The designers accepted a trade-off: semaglutide binds the GLP-1 receptor about three times less tightly than its predecessor, liraglutide, in exchange for much stronger albumin binding. In mini-pigs, its plasma half-life reached 46 hours. A 2019 review by Knudsen and Lau traces the path from liraglutide to semaglutide. Semaglutide is also the first GLP-1 drug made as a daily tablet. University of Toronto researcher Daniel Drucker, in a 2020 Nature Reviews Drug Discovery review, called the approval of oral semaglutide a landmark, since peptides usually break down in the gut. The tablet relies on an absorption enhancer to get a small share of the drug across the stomach wall. Our semaglutide guide covers its research history.

How Tirzepatide Works

Tirzepatide is a fatty acid-modified peptide that activates both the GIP and GLP-1 receptors. Pharmacology studies describe it as “imbalanced,” engaging the GIP receptor more than the GLP-1 receptor, and “biased” at the GLP-1 receptor, favoring one signaling route over another. 🧪 and 🐭 Eli Lilly introduced the molecule, then called LY3298176, in a 2018 Molecular Metabolism paper describing it as “a fatty acid modified peptide with dual GIP and GLP-1 receptor agonist activity designed for once-weekly subcutaneous administration.” The research question was whether GIP “adds to the established clinical benefits of selective GLP-1 receptor agonists.” 🧪 A 2020 JCI Insight study by Willard and colleagues, mostly Lilly scientists, found “a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor.” At the GLP-1 receptor, tirzepatide favored cAMP signaling over β-arrestin recruitment, which pulled the receptor into the cell less than natural GLP-1 does. The authors proposed that this combination of imbalance and bias may explain its trial results. In plain terms, tirzepatide behaves mostly like GIP at one receptor and like a modified, selective version of GLP-1 at the other, which makes it more than a simple sum of two hormones. 🐭 and 👤 Gastric emptying studies by Urva and colleagues found tirzepatide slowed emptying much like GLP-1 drugs, with the effect fading over repeated doses. Our tirzepatide guide has more.

What Head-to-Head Human Trials Report

The SURMOUNT-5 Trial

👤 SURMOUNT-5, published in the New England Journal of Medicine in 2025, was a phase 3b open-label trial in 751 adults with obesity but without type 2 diabetes. Participants received the highest dose of each drug they could tolerate, once weekly, for 72 weeks. Average weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Waist circumference fell by 18.4 cm and 13.0 cm, respectively. The trial was led by Louis Aronne of Weill Cornell Medicine and funded by Eli Lilly.

Earlier Comparison in Type 2 Diabetes

👤 SURPASS-2 randomized 1,879 adults with type 2 diabetes to one of three tirzepatide doses or semaglutide for 40 weeks. HbA1c, a three-month blood sugar marker, fell by 2.01 to 2.30 percentage points with tirzepatide and 1.86 with semaglutide. Weight loss was 1.9 to 5.5 kg greater with tirzepatide. The semaglutide dose used was lower than the one later studied for weight management.

Limits

Both trials were open-label, so participants knew which drug they received. Both were funded by Lilly, tirzepatide’s maker. SURPASS-2 compared tirzepatide against a lower semaglutide dose. 👤 Observational research adds context with its own limits: a 2024 JAMA Internal Medicine cohort of 18,386 matched US adults found greater weight loss with tirzepatide at 3, 6 and 12 months, with similar rates of gastrointestinal adverse events, though observational designs can’t fully account for who received which drug.

Adverse Events Reported in Trials

In both drugs’ trials, gastrointestinal events such as nausea, diarrhea and vomiting were the most common adverse events, mostly mild to moderate and concentrated during dose increases. Both FDA labels carry a boxed warning about thyroid C-cell tumors, based on rodent findings. 👤 SURPASS-2 rates. Nausea occurred in 17% to 22% of tirzepatide patients and 18% of semaglutide patients, diarrhea in 13% to 16% and 12%, and vomiting in 6% to 10% and 8%. Serious adverse events were reported in 5% to 7% with tirzepatide and 3% with semaglutide. 👤 SURMOUNT-5. “The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation.” 🏛️ Boxed warning. The FDA labels for Wegovy and Zepbound both carry a boxed warning about thyroid C-cell tumors seen in rodents, stating it’s “unknown whether” each drug causes such tumors, including medullary thyroid carcinoma, in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. These are trial and label facts. Comparing overall tolerability for any individual is a clinical question.

Regulatory Status and the Compounding Question

Both drugs are FDA-approved prescription medicines. During supply shortages that ran from 2022 into early 2025, compounding pharmacies were allowed to make copies. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, and its statement to compounders set end dates for that flexibility in early 2025. The FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that “compounded drugs are not FDA approved,” that salt forms “are different active ingredients than are used in the approved drugs,” and warns about products “falsely labeled ‘for research purposes’ or ‘not for human consumption.'” That last point explains why research-market “semaglutide” or “tirzepatide” vials aren’t the approved medicines, whatever their labels say. Our weight and metabolism research hub lists related compounds, such as AOD-9604.

FAQ

What is the difference between semaglutide and tirzepatide?

Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GIP and GLP-1 receptors and, in pharmacology studies, engages the GIP receptor more strongly. Both are once-weekly peptide medicines approved for type 2 diabetes and weight management under different brand names.

Is tirzepatide a GLP-1 agonist?

Partly. Tirzepatide is a dual agonist, activating both the GLP-1 and GIP receptors. Pharmacology research describes it as imbalanced toward GIP and biased at the GLP-1 receptor, favoring cAMP signaling. It’s often grouped with GLP-1 drugs, but its mechanism is broader.

Have semaglutide and tirzepatide been compared head to head?

Yes, in two open-label randomized trials. SURPASS-2 studied 1,879 adults with type 2 diabetes over 40 weeks, and SURMOUNT-5 studied 751 adults with obesity without diabetes over 72 weeks. Both were funded by Eli Lilly and reported greater weight reduction with tirzepatide.

What gastrointestinal adverse events did trials report for each?

Nausea, diarrhea and vomiting were most common for both. In SURPASS-2, nausea occurred in 17% to 22% of tirzepatide patients and 18% of semaglutide patients, mostly mild to moderate and during dose increases.

Are semaglutide and tirzepatide FDA approved?

Yes. Semaglutide is approved as Ozempic, Rybelsus and Wegovy, and tirzepatide as Mounjaro and Zepbound, for specific indications on their labels. Compounded versions and research-labeled products aren’t FDA-approved. Our peptide comparisons hub and what peptides are explainer add background.

Closing Note

Semaglutide refined one gut hormone. Tirzepatide combined two, tilted toward GIP. Head-to-head trials report larger weight and glucose changes with tirzepatide, within open-label, sponsor-funded designs. Decisions about these medicines belong with a clinician.